Ponatinib
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Ponatinib: From BCR-ABL1-Positive Chronic Myelogenous Leukaemia to Gingival Fibromatosis
One-Sentence Summary
Ponatinib is a multi-target tyrosine kinase inhibitor originally used to treat BCR-ABL1-positive chronic myelogenous leukaemia. The TxGNN model predicts it may be effective for gingival fibromatosis (fibromatosis, gingival), but no clinical trials and no publications currently support this specific prediction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Chronic myelogenous leukaemia, BCR-ABL1 positive (from the knowledge graph; the Singapore licence records contain no indication text) |
| Predicted New Indication | Fibromatosis, gingival |
| TxGNN Prediction Score | 99.04% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 2 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available. Based on known information, ponatinib is a multi-target tyrosine kinase inhibitor. Its efficacy in BCR-ABL1-positive leukaemia is established, and it is also known to act on FGFR, PDGFR, SRC, VEGFR and KIT.
Gingival fibromatosis is a fibroproliferative condition. A link through PDGFR/FGFR signalling is theoretically plausible, but nothing in the data compiled for this report confirms it. The prediction currently rests on the model score alone.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN15581P | ICLUSIG TABLET 15 MG | Film-coated tablet | Not stated in the licence record |
| SIN15582P | ICLUSIG TABLET 45 MG | Film-coated tablet | Not stated in the licence record |
Both licences are single-ingredient products, currently valid, and manufactured by Patheon Inc. and Takeda Ireland Limited.
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (multi-target tyrosine kinase inhibitor) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert; at minimum, blood counts and liver and renal function, plus cardiovascular monitoring given the reported cardiotoxicity |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
No package insert warnings or contraindications were available for this report, so please refer to the package insert for these.
Drug Interactions: The interaction screen returned 100 interacting drugs. The 20 reviewed here include the following.
- Major: acetylsalicylic acid (aspirin) and clarithromycin.
- Moderate: loperamide, aprepitant, dexamethasone, naldemedine, naltrexone, metronidazole and miconazole.
- Minor: acid-suppressing agents (famotidine, ranitidine, cimetidine, nizatidine, and the proton pump inhibitors omeprazole, lansoprazole, pantoprazole, rabeprazole and dexlansoprazole), magnesium oxide and naloxegol.
Published reviews also describe cardiovascular toxicity and pulmonary complications with ponatinib and related BCR-ABL inhibitors. These risks matter when considering use in a non-life-threatening condition.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a high model score (Level L5), with no trials or publications for gingival fibromatosis. Ponatinib carries notable cardiovascular and thrombotic risks, which makes it hard to justify for a non-malignant fibroproliferative condition without supporting evidence.
To proceed, the following is needed:
- Mechanistic data (MOA) and a documented rationale linking PDGFR/FGFR signalling to gingival fibromatosis
- Preclinical or clinical evidence in this condition
- Package insert warnings and contraindications from the HSA
- A benefit-risk assessment that accounts for ponatinib's cardiovascular safety profile
Other Predicted Indications (for Reference)
Among the other top-ranked predictions, liposarcoma has the most relevant supporting evidence, though only preclinical. A 2017 kinase-profiling and drug-screening study identified druggable kinase targets in liposarcoma (PMID 29132397). This study does not name ponatinib, so the link remains unconfirmed. It is suitable as a research question rather than a development candidate. The remaining predictions have no direct supporting evidence; their literature consists mainly of general ponatinib or kinase-inhibitor papers.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.